Description de l'entreprise
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil and Colombia and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights from Zambon for the US. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
Conseil d'administration & Conseil de surveillance
| PDG |
| Stefan Weber |
| Conseil d'administration |
| Ravi Anand, Laura Faravelli, Roberto Galli, Dennis Dionne, Filippo Moriggia |
| Conseil de surveillance |
| Dr. Ulrich Köstlin, Patrick Langlois, Luca Benatti, Gillian Dines, Stefan Weber |
Données de l'entreprise
| Nom: |
Newron Pharmaceuticals S.p.A. |
| Adresse: |
Newron Pharmaceuticals SpA, via Antonio Meucci 3,I-20091 Bresso (Mi) |
| Téléphone: |
+39-02-610-3461 |
| Fax: |
+39-02-610-34654 |
| Courriel: |
info@newron.com
|
| Internet: |
www.newron.com/en |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
91.91% |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
Stefan Weber |
| Téléphone IR: |
+39-02-610-34609 |
| IR-Fax: |
- |
| E-mail IR: |
ir@newron.com
|
